全文获取类型
收费全文 | 34910篇 |
免费 | 2932篇 |
国内免费 | 1125篇 |
专业分类
耳鼻咽喉 | 290篇 |
儿科学 | 245篇 |
妇产科学 | 1868篇 |
基础医学 | 6536篇 |
口腔科学 | 692篇 |
临床医学 | 3309篇 |
内科学 | 3863篇 |
皮肤病学 | 226篇 |
神经病学 | 3475篇 |
特种医学 | 1809篇 |
外国民族医学 | 1篇 |
外科学 | 4047篇 |
综合类 | 4600篇 |
现状与发展 | 6篇 |
预防医学 | 1595篇 |
眼科学 | 605篇 |
药学 | 3682篇 |
11篇 | |
中国医学 | 1171篇 |
肿瘤学 | 936篇 |
出版年
2023年 | 434篇 |
2022年 | 682篇 |
2021年 | 1124篇 |
2020年 | 1087篇 |
2019年 | 999篇 |
2018年 | 1060篇 |
2017年 | 1023篇 |
2016年 | 1025篇 |
2015年 | 1101篇 |
2014年 | 2011篇 |
2013年 | 2161篇 |
2012年 | 1872篇 |
2011年 | 2099篇 |
2010年 | 1711篇 |
2009年 | 1631篇 |
2008年 | 1584篇 |
2007年 | 1636篇 |
2006年 | 1535篇 |
2005年 | 1337篇 |
2004年 | 1255篇 |
2003年 | 1185篇 |
2002年 | 990篇 |
2001年 | 842篇 |
2000年 | 723篇 |
1999年 | 618篇 |
1998年 | 602篇 |
1997年 | 612篇 |
1996年 | 512篇 |
1995年 | 529篇 |
1994年 | 482篇 |
1993年 | 436篇 |
1992年 | 416篇 |
1991年 | 404篇 |
1990年 | 338篇 |
1989年 | 309篇 |
1988年 | 277篇 |
1987年 | 245篇 |
1986年 | 195篇 |
1985年 | 272篇 |
1984年 | 236篇 |
1983年 | 142篇 |
1982年 | 218篇 |
1981年 | 199篇 |
1980年 | 158篇 |
1979年 | 137篇 |
1978年 | 128篇 |
1977年 | 113篇 |
1976年 | 105篇 |
1975年 | 43篇 |
1974年 | 39篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
101.
《Biomaterials》2015
Controlling cellular alignment is critical in engineering intestines with desired structure and function. Although previous studies have examined the directional alignment of cells on the surface (x–y plane) of parallel fibers, quantitative analysis of the cellular alignment inside implanted scaffolds with oriented fibers has not been reported. This study examined the cellular alignment in the x–z and y–z planes of scaffolds made with two layers of orthogonally oriented fibers. The cellular orientation inside implanted scaffolds was evaluated with immunofluorescence. Quantitative analysis of coherency between cell orientation and fiber direction confirmed that cells aligned along the fibers not only on the surface (x–y plane) but also inside the scaffolds (x–z & y–z planes). Our study demonstrated that two layers of orthogonally aligned scaffolds can generate the histological organization of cells similar to that of intestinal circular and longitudinal smooth muscle. 相似文献
102.
目的探讨竖脊肌平面阻滞(ESPB)超前镇痛对老年胸腔镜肺癌根治术患者心肌的保护作用。 方法选择在惠州市中心人民医院择期行胸腔镜肺癌根治术的老年患者40例,按照患者意愿分组,其中19例采用ESPB联合全身麻醉(观察组),21例采用单纯全身麻醉(对照组)。在两组诱导前(T0)、手术开始1 h(T1)、手术结束时(T2)及术后4 h(T3)检测患者的肌钙蛋白Ⅰ(cTnⅠ)、心型脂肪酸结合蛋白(H-FABP)、肌酸激酶同工酶(CK-MB),并记录各时间点的平均动脉压(MAP)和心率。计量资料的组间比较采用t检验,重复测量资料采用重复测量方差分析。 结果两组患者MAP、心率、cTnⅠ、H-FABP、CK-MB的差异均呈现组间效应、时间效应和交互效应(MAP:F=24.021、33.512、9.184,心率:F=10.340、46.992、3.494,cTnⅠ:F=5.354、691.994、64.177,H-FABP:F=7.906、14.067、11.560,CK-MB:F=15.926、84.106、4.116,P<0.05或0.01)。与T0时间点比较,两组患者T1、T2、T3时间点MAP、心率、H-FABP、CK-MB均出现明显变化(P<0.05),T2、T3时间点cTnⅠ出现明显变化(P<0.05)。 结论老年胸腔镜肺癌根治术中应用ESPB超前镇痛,可明显降低心肌损伤相关因子水平,起到心肌保护作用。 相似文献
103.
104.
《Clinical neurophysiology》2020,131(1):259-264
ObjectivesFasciculation potentials (FP) are an important consideration in the electrophysiological diagnosis of ALS. Muscle ultrasonography (MUS) has a higher sensitivity in detecting fasciculations than electromyography (EMG), while in some cases, it is unable to detect EMG-detected fasciculations. We aimed to investigate the differences of FP between the muscles with and without MUS-detected fasciculations (MUS-fas).MethodsThirty-one consecutive patients with sporadic ALS were prospectively recruited and in those, both needle EMG and MUS were performed. Analyses of the amplitude, duration, and number of phases of EMG-detected FPs were performed for seven muscles per patient, and results were compared between the muscles with and without MUS-fas in the total cohort.ResultsThe mean amplitude and phase number of FP were significantly lower in patients with EMG-detected FP alone (0.39 ± 0.25 mV and 3.21 ± 0.88, respectively) than in those with both FP and MUS-fas (1.22 ± 0.92 mV and 3.74 ± 1.39, respectively; p < 0.0001 and p = 0.017, Welch’s t-test).ConclusionSmall FP may be undetectable with MUS. MUS cannot replace EMG in the diagnostic approach for ALS.SignificanceClinicians should use a combination of EMG and MUS for the detection and quantitative analysis of fasciculation in ALS. 相似文献
105.
106.
107.
108.
109.
Se-Jin Lee Adam Lehar Yewei Liu Chi Hai Ly Quynh-Mai Pham Michael Michaud Renata Rydzik Daniel W. Youngstrom Michael M. Shen Vesa Kaartinen Emily L. Germain-Lee Thomas A. Rando 《Proceedings of the National Academy of Sciences of the United States of America》2020,117(49):30907
Myostatin (MSTN) is a transforming growth factor-β (TGF-β) family member that normally acts to limit muscle growth. The function of MSTN is partially redundant with that of another TGF-β family member, activin A. MSTN and activin A are capable of signaling through a complex of type II and type I receptors. Here, we investigated the roles of two type II receptors (ACVR2 and ACVR2B) and two type I receptors (ALK4 and ALK5) in the regulation of muscle mass by these ligands by genetically targeting these receptors either alone or in combination specifically in myofibers in mice. We show that targeting signaling in myofibers is sufficient to cause significant increases in muscle mass, showing that myofibers are the direct target for signaling by these ligands in the regulation of muscle growth. Moreover, we show that there is functional redundancy between the two type II receptors as well as between the two type I receptors and that all four type II/type I receptor combinations are utilized in vivo. Targeting signaling specifically in myofibers also led to reductions in overall body fat content and improved glucose metabolism in mice fed either regular chow or a high-fat diet, demonstrating that these metabolic effects are the result of enhanced muscling. We observed no effect, however, on either bone density or muscle regeneration in mice in which signaling was targeted in myofibers. The latter finding implies that MSTN likely signals to other cells, such as satellite cells, in addition to myofibers to regulate muscle homeostasis.Myostatin (MSTN) is a secreted signaling molecule that normally acts to limit skeletal muscle growth (for review, see ref. 1). Mice lacking MSTN exhibit dramatic increases in muscle mass throughout the body, with individual muscles growing to about twice the normal size (2). MSTN appears to play two distinct roles in regulating muscle size, one to regulate the number of muscle fibers that are formed during development and a second to regulate the growth of those fibers postnatally. The sequence of MSTN has been highly conserved through evolution, with the mature MSTN peptide being identical in species as divergent as humans and turkeys (3). The function of MSTN has also been conserved, and targeted or naturally occurring mutations in MSTN have been shown to cause increased muscling in numerous species, including cattle (3–5), sheep (6), dogs (7), rabbits (8), rats (9), swine (10), goats (11), and humans (12). Numerous pharmaceutical and biotechnology companies have developed biologic agents capable of blocking MSTN activity, and these have been tested in clinical trials for a wide range of indications, including Duchenne and facioscapulohumeral muscular dystrophy, inclusion body myositis, muscle atrophy following falls and hip fracture surgery, age-related sarcopenia, Charcot–Marie–Tooth disease, and cachexia due to chronic obstructive pulmonary disease, end-stage kidney disease, and cancer.The finding that certain inhibitors of MSTN signaling can increase muscle mass even in Mstn−/− mice revealed that the function of MSTN as a negative regulator of muscle mass is partially redundant with at least one other TGF-β family member (13, 14), and subsequent studies have identified activin A as one of these cooperating ligands (15, 16). MSTN and activin A share many key regulatory and signaling components. For example, the activities of both MSTN and activin A can be modulated extracellularly by naturally occurring inhibitory binding proteins, including follistatin (17, 18) and the follistatin-related protein, FSTL-3 or FLRG (19, 20). Moreover, MSTN and activin A also appear to share receptor components. Based on in vitro studies, MSTN is capable of binding initially to the activin type II receptors, ACVR2 and ACVR2B (also called ActRIIA and ActRIIB) (18) followed by engagement of the type I receptors, ALK4 and ALK5 (21). In previous studies, we presented genetic evidence supporting a role for both ACVR2 and ACVR2B in mediating MSTN signaling and regulating muscle mass in vivo. Specifically, we showed that mice expressing a truncated, dominant-negative form of ACVR2B in skeletal muscle (18) or carrying deletion mutations in Acvr2 and/or Acvr2b (13) have significantly increased muscle mass. One limitation of the latter study, however, was that we could not examine the consequence of complete loss of both receptors using the deletion alleles, as double homozygous mutants die early during embryogenesis (22). Moreover, the roles that the two type I receptors, ALK4 and ALK5, play in regulating MSTN and activin A signaling in muscle in vivo have not yet been documented using genetic approaches. Here, we present the results of studies in which we used floxed alleles for each of the type II and type I receptor genes in order to target these receptors alone and in combination in muscle fibers. We show that these receptors are functionally redundant and that signaling through each of these receptors contributes to the overall control of muscle mass. 相似文献
110.